Our vision is that cellular humanization of swine could provide unlimited supplies of therapeutic cells, tissues, and organs. Regenevida is pioneering individualized regenerative medicine by leveraging Recombinetics’ leading gene editing platform and expertise to develop swine as a production system for cultivating patient cells, tissues, and organs for human therapeutic applications.
Each step along the path to organ development presents large-scale market opportunities with strong revenue potential. Strategic partnerships with leading hospitals and medical research institutions are vital elements for Regenevida’s success. With its first-mover advantage, Recombinetics is already entering into collaborative R&D contracts.